Actually, I was just calculating the results for Kintara's drug for their "head-to-head" trial with Kazia (VAL-083 adjuvant monotherapy), and it seems wrong. I tabulated all patient PFS data for those patients which have already progressed (21 patients) and got the following numbers:
From these 21 patients, the median PFS is 8.2 months.
Now, they had 6 other patients which hadn't progressed yet.
1 - 14 2 - 12.2 3 - 10 4 - 9.4 5 - 5.5 6 -4
However, even if we assume they all live to be 100, the median PFS only goes to patient #8 above, which is 9.2 months. If patients #5 and #6 in this bottom set progress sooner than 8.2 months, then the median PFS will be 8.5 months. So, I think the range for mPFS for Kintara should be 8.5-9.2. I don't know how they got 10.
KZA Price at posting:
$1.57 Sentiment: Buy Disclosure: Held